Current Trials

FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (cancer that typically occurs in the urinary system).

The purpose of this trial is to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy.

Non-metastatic breast, colorectal, gastro-oesophagal or prostate cancer which can be treated and potentially cured.

The purpose of this study is to evaluate the the effects of aspirin on disease recurrence and survival in patients who have had primary curative therapy for common non-metastatic solid tumours.

Early stage breast cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab.

Ovarian cancer

The purpose of this study is to investigate if two medications; Rucaparib and Nivolumab used together or separately are better than the current best available treatment for patients who have had platinum-based chemotherapy for ovarian cancer.

Patients with complete resection of Stage IIIa/b/c/d or Stage IV Melanoma

The purpose of this trial is to compare whether there is a difference in treatment outcome for patients treated with Nivolumab manufactured by Process C or the newly developed comparable drug manufactured by Process D.

Children, adolescents, and young adults with Classic Hodgkin Lymphoma whose disease has come back or did not respond to initial treatment.

The purpose of this study is to determine whether certain drug combinations are safe and effective.

Indolent (grow slowly) Non-Hodgkin’s Lymphoma that have returned after previous treatment.

The purpose of this study is to evaluate the efficacy and safety of copanlisib in combination with standard immunochemotherapy.

Patients with cancer of the colon which has spread (metastasised).

The aim of the study is to identify and confirm one or more biomarkers (a biological substance) in blood and/or tissue, which will help us to identify the patients, who are going to respond to their treatment.

Advanced oesophago-gastric or colorectal cancer

The purpose of this trial is to determine the safety and efficacy of the drug lithium and the optimum dose when used with standard chemotherapy.

Bile duct cancer that is inoperable or has spread, in patients that test positive for FGFR2 gene fusion, or, FGFR2 gene mutations or amplifications.

To investigate the effects of the drug derazantinib (formerly ARQ 087) in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholangiocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion or FGFR2 gene mutations or amplifications.

Advanced/metastatic renal cell carcinoma (kidney cancer).

The purpose of this trial is to assess the safety and efficacy of the drug lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of participants with advanced renal cell carcinoma.

Cervical cancer

The purpose of the study is to investigate if Tisotumab Vedotin (HuMax®-TF-ADC) is safe and has an additive effect when used with other anti-cancer medications in the treatment of recurrent or advanced cervical cancer.

Patients with advanced stage RET-rearranged NSCLC, treated with at least one platinum based systemic chemotherapy regimen.

The primary objective is to assess the efficacy of alectinib in terms of best overall response (OR) assessed by RECIST 1.1., from the start of trial treatment across all time points until the end of trial treatment

Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement

The purpose of this trial is to evaluate the efficacy of pemigatinib versus standard chemotherapy in the first-line treatment of patients with Unresectable or Metastatic Cholangiocarcinoma, whos tumors harbor FGFR2 gene rearrangement.

For patients with non-small cell lung cancer (NSCLC) who are unsuitable for surgery or stereotactic ablative body radiation therapy (SABR)

The primary objective of this study is to assess the safe delivery of an achievable level of dose escalation in a dose‐escalated and
intensified radiation therapy regime delivered via VMAT/IMRT and focussed on the GTV, by the
proportion of grade ≥3 toxicities per NCI‐CTCAE V4 determined to be related to radiation
therapy.